Search Results

First Procedures With Avinger's Next-Generation Pantheris Lumivascular System Performed in Europe

January 3, 2018—Avinger, Inc. announced the successful treatment of the first seven patients with its next-generation Pantheris Lumivascular atherectomy system.

Avinger's Pantheris OCT–Guided Directional Atherectomy System Studied in VISION IDE Trial

November 2, 2015—Results of the VISION investigational device exemption (IDE) trial for the Pantheris optical coherence tomography (OCT)–guided directional atherectomy system (Avinger, Inc.) were presented by Arne Schwindt, MD, during the first Late-Breaking Trials session at VIVA 15, the 13th annual Vascular InterVentional Advances meeting.

Avinger Announces Interim 6-Month VISION Trial Results

October 13, 2015—Avinger, Inc. announced that interim 6-month results for its VISION clinical trial were presented at TCT 2015, the Transcatheter Cardiovascular Therapeutics scientific symposium being held October 11–15 in San Francisco, California.

Results of Clinical Study Support Avinger Ocelot OCT Catheter for Crossing CTOs

October 11, 2012—Avinger, Inc. (Redwood City, CA) announced results for its CONNECT II global clinical trial.

Primary Endpoint Data From NEAT Presented for TVA's everlinQ endoAVF System

January 28, 2016—TVA Medical, Inc. announced that primary endpoint data from the Novel Endovascular Access Trial (NEAT) evaluating the company’s everlinQ endovascular arteriovenous fistula (endoAVF) system were presented by Charmaine E. Lok, MD, at LINC 2016, the Leipzig Interventional Course held January 26–29 in Leipzig, Germany. A live case demonstrating the use of the everlinQ endoAVF system was conducted at LINC by Arne Schwindt, MD, vascular surgeon at St. Franziskus Hospital in Muenster, Germany.

Penumbra’s Lightning Bolt 12 and Lightning Bolt 6X With Trax Approved in Europe

December 3, 2025—Penumbra Inc. announced it has secured CE Mark approval for its Lightning Bolt 12 and Lightning Bolt 6X with Trax.

CONNECT II Study of Avinger's Ocelot Catheter Completes Enrollment

July 10, 2012—Avinger, Inc. (Redwood City, CA) announced that enrollment has been completed in the CONNECT II global clinical trial for the company's Ocelot crossing catheter.

Covidien's EverFlex Self-Expanding Peripheral Stent With Entrust Delivery System Gains CE Mark Approval

January 23, 2013—Covidien (Mansfield, MA) announced CE Mark approval for its EverFlex self-expanding peripheral stent with Entrust delivery system.

Avinger Begins CONNECT II Trial of Ocelot CTO Catheter With OCT

March 14, 2012—Avinger, Inc. (Redwood City, CA) announced commencement of the CONNECT II global clinical trial of the company's Ocelot catheter, which uses optical coherence tomography (OCT) for crossing chronic total occlusions (CTO) in patients with peripheral arterial disease. The first patient in the United States was enrolled on March 6 by Ian Cawich, MD, at the Arkansas Heart Hospital in Little Rock.

First Patient Enrollment in Shape Memory Medical AAA-SHAPE Study

September 16, 2020—Shape Memory Medical Inc. announced the initiation of the company’s AAA-SHAPE prospective safety study of the Impede-FX embolization plug device when used for abdominal aortic aneurysm (AAA) sac filling during elective endovascular aneurysm repair (EVAR).